PubMed Health⌕ Search

Biomedical subjects

Bernard J Roth

Publications and source records attributed to Bernard J Roth.

3 recordsLinked to original sources

Instruction of hospitalized patients by respiratory therapists on metered-dose inhaler use leads to decrease in patient errors.

BACKGROUND: Hospitalized patients have been shown to make several errors in using metered-dose inhalers (MDIs), which can lead to poor medication delivery. METHODS: This study was designed to look at the potential benefit of a respiratory therapist (RT) giving instruction on the use of MDIs to hospitalized patients with obstructive lung disease. A baseline group of 58 patients was observed by a physician while performing 2 actuations of their MDI and the number of errors they committed, based on the National Institutes of Health's recommended 8 steps for proper MDI use, was recorded. After a program of MDI instruction (which included encouragement to use a spacer) by an RT was performed, a second group of hospitalized patients was again observed by a physician to determine if their error rate was reduced. RESULTS: The baseline error rate was 6.72 (out of 15 possible) errors per patient, and improved to 2.43 errors per patient after RT-provided instruction (p < 0.001). This improvement was still significant after controlling for an increased use of spacers in the post-instruction group of patients (27.6% and 91.7% spacer use before and after education). CONCLUSIONS: Instruction of hospitalized patients with obstructive lung disease by an RT improves their correct use of MDIs and increases their use of spacers while in the hospital.

Administration, Inhalation↗

Topotecan-induced bronchiolitis.

Topotecan HCl is an antitumor drug exhibiting topoisomerase 1-inhibitory activity. Topotecan is used in the treatment of metastatic carcinoma of the ovary and as second-line treatment of small-cell lung cancer. Reported dose-limiting adverse reactions to topotecan are primarily hematologic in nature. To date, only one other case of lung toxicity in a patient taking topotecan has been reported. The authors describe the development of obliterative bronchiolitis, as evidenced by radiographic and pulmonary function testing abnormalities, in a 61-year-old woman who presented with dyspnea, and who was receiving topotecan for peritoneal carcinomatosis.

Antineoplastic Agents↗

Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin.

Churg-Strauss syndrome is an extremely rare disease, and even less common in women of childbearing age. The initial management of Churg-Strauss syndrome consists of high doses of corticosteroids. Patients with severe disease, or those who are unresponsive to corticosteroids, usually are treated with cytotoxic drugs. Intravenous immunoglobulin (IVIg) has become a promising, but not completely accepted, form of treatment for systemic vasculitis that is unresponsive to standard therapy. We present a case of a woman diagnosed with Churg-Strauss syndrome that was refractory to corticosteroid and cyclophosphamide treatment. When she was found to be 3 months pregnant, treatment with IVIg was instituted with successful results. This case not only supports the beneficial effect of IVIg in Churg-Strauss syndrome, it illustrates its successful use in a patient who was pregnant.

Journal Article↗